Table 2 Cost-Effectiveness analysis results of the included studies
Study | Main Conclusion |
|---|---|
Chaudhary (2021) | Trial data demonstrated that nivolumab is associated with increased OS and response rates compared with docetaxel in patients with advanced pre-treated squamous, and suggested that nivolumab generates more favorable ICERs |
Gao (2018) | The treatment with nivolumab cannot be considered cost-effective. |
Goeree (2016) | For patients with advanced squamous NSCLC, nivolumab was found to have the highest expected per patient cost, but also higher LYs and QALYs compared to docetaxel. |
Chouaid (2019) | Pembrolizumab appears cost-effective versus chemotherapy for first-line treatment of PD-L1positive (50%) metastatic NSCLC patients |
Rothwell (2021) | Nivolumab versus docetaxel is cost effective for treating locally advanced/metastatic squamous NSCLC |
Hu (2023) | Nivolumab yielded survival and quality-adjusted survival benefits at incremental cost versus docetaxel in aNSCLC. |
Zhao (2023) | Paclitaxel and platinum combined with camrelizumab are the cost-effective treatment |
Cheng (2022) | For Chinese patients with driver-negative advanced or metastatic sqNSCLC, reserving the use of sintilimab until the second-line represents a cost-effective treatment strategy compared with the first-line treatment. |
Insinga (2019) | The addition of pembrolizumab to chemotherapy is projected to approximately double life expectancy, and can be a cost-effective first-line treatment for eligible metastatic squamous NSCLC patients for whom chemotherapy is currently administered. |
Liu (2022) | For the squamous NSCLC patient population, the first-line Pembro + Chemo as a cost-effective treatment. |
Zhou (2023) | Toripalimab plus chemotherapy was an optimal choice as first-line treatment. |
Li (2022) | Sugemalimab plus chemotherapy was not cost-effective in comparison to placebo plus chemotherapy as first-line treatment for NSCLC, regardless of PD-L1 tumor expression level and pathological subtype. |
Chen (2022) | Compared with pembrolizumab + chemotherapy, sintilimab + chemotherapy is more cost-effective for first-line treatment in Chinese patients with advanced or metastatic squamous NSCLC. |
Shao (2022) | Camrelizumab plus chemotherapy was unlikely to be cost-effective compared with chemotherapy in the first line therapy of sq-NSCLC from a perspective of the Chinese healthcare system |
Zhang (2023) | Toripalimab plus chemotherapy was cost-effective compared to chemotherapy for patients with advanced NSCLC in China. |